Age-stratified reference intervals unlock the clinical potential of circulating cell-free DNA as a biomarker of poor outcome for healthy individuals and patients with colorectal cancer.
biomarker
circulating cell-free DNA
colorectal cancer
overall survival
reference intervals
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
01 04 2021
01 04 2021
Historique:
received:
31
08
2020
revised:
17
11
2020
accepted:
02
12
2020
pubmed:
16
12
2020
medline:
6
8
2021
entrez:
15
12
2020
Statut:
ppublish
Résumé
Circulating cell-free DNA (cfDNA) has spurred much interest as a biomarker in oncology. However, inter- and intra-individual cfDNA levels vary greatly. Consequently, in order to base clinical decisions on cfDNA measurements, normal reference intervals are essential to avoid that ordinary variation is confused with clinically relevant change. The lack of reference intervals may potentially explain the ambiguous results reported in the field. Our study aimed to establish reference intervals and to evaluate the association between cfDNA and demographic and clinical variables, including colorectal cancer (CRC). Plasma samples and clinical data from 2817 subjects were collected including 1930 noncancer individuals and 887 CRC patients. cfDNA was measured using droplet digital polymerase chain reaction (PCR). The large cohort combined with robust cfDNA quantification enabled establishment of reference intervals (<67 years: 775-4860 copies/mL; ≥67 years: 807-6561 copies/mL). A cfDNA level above the age-stratified 90% percentile was prognostic of reduced survival in both noncancer individuals and CRC patients, with HR values of 2.56 and 2.01, respectively. Moreover, cfDNA levels increased significantly with age, elevated BMI and chronic diseases. In CRC, the cfDNA level was increased for Stage IV, but not Stage I to Stage III cancer. In summary, the use of reference intervals revealed that high cfDNA levels were predictive of shorter survival in both noncancer individuals and CRC patients, and that CRC development did not affect the cfDNA level until metastatic dissemination. Furthermore, cfDNA levels were impacted by age and chronic diseases. Conclusively, our study presents reference intervals that will help pave the way for clinical utilization of cfDNA.
Identifiants
pubmed: 33320961
doi: 10.1002/ijc.33434
pmc: PMC7898909
doi:
Substances chimiques
Biomarkers, Tumor
0
Cell-Free Nucleic Acids
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1665-1675Informations de copyright
© 2020 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
Références
Mech Ageing Dev. 2011 Jan-Feb;132(1-2):20-6
pubmed: 21078336
Intensive Care Med Exp. 2019 May 22;7(1):29
pubmed: 31119471
Am J Med Sci. 2018 Aug;356(2):121-129
pubmed: 30219153
Clin Chem. 2002 Feb;48(2):338-52
pubmed: 11805016
J Intern Med. 2018 Oct;284(4):418-426
pubmed: 29687943
Technol Cancer Res Treat. 2018 Jan 1;17:1533033818791794
pubmed: 30223720
BMJ. 2008 Jun 30;337:a516
pubmed: 18595935
EBioMedicine. 2019 Nov;49:284-290
pubmed: 31648993
JMIR Res Protoc. 2016 Sep 13;5(3):e182
pubmed: 27624815
Int J Cancer. 2011 Oct 15;129(8):1848-58
pubmed: 21154748
Pathol Oncol Res. 2017 Jul;23(3):699-706
pubmed: 28035516
Clin Chem. 2019 May;65(5):623-633
pubmed: 30792266
Int J Cancer. 2017 Apr 15;140(8):1888-1898
pubmed: 27943272
Front Immunol. 2019 Mar 19;10:502
pubmed: 30941136
Clin Epigenetics. 2019 Nov 14;11(1):158
pubmed: 31727158
Crit Care. 2017 Jan 24;21(1):14
pubmed: 28118843
J Cancer. 2016 Jun 04;7(9):1105-13
pubmed: 27326254
Atherosclerosis. 2014 Mar;233(1):268-71
pubmed: 24529155
J Clin Oncol. 2018 Jun 1;36(16):1631-1641
pubmed: 29504847
Clin Cancer Res. 2017 Sep 15;23(18):5437-5445
pubmed: 28600478
Clin Chem. 2013 Jun;59(6):892-902
pubmed: 23570709
Clin Chim Acta. 2020 Aug;507:39-53
pubmed: 32272156
Int J Cancer. 2021 Apr 1;148(7):1665-1675
pubmed: 33320961
Mol Oncol. 2020 Aug;14(8):1670-1679
pubmed: 32471011
Clin Chim Acta. 2015 Jun 15;446:141-6
pubmed: 25896958
Sci Transl Med. 2014 Feb 19;6(224):224ra24
pubmed: 24553385
Br J Cancer. 2014 Oct 14;111(8):1482-9
pubmed: 25157833
Cell. 2016 Jan 14;164(1-2):57-68
pubmed: 26771485
Cancer Cell. 2019 Oct 14;36(4):350-368
pubmed: 31614115
Transl Psychiatry. 2018 Oct 29;8(1):236
pubmed: 30374018
Clin Chim Acta. 2013 Sep 23;424:222-30
pubmed: 23727028
Sci Rep. 2019 Mar 26;9(1):5220
pubmed: 30914716
Brain Inj. 2017;31(10):1369-1375
pubmed: 28585898
JAMA Oncol. 2019 May 9;:
pubmed: 31070691
Nature. 2017 Apr 26;545(7655):446-451
pubmed: 28445469
Scand J Public Health. 2011 Jul;39(7 Suppl):30-3
pubmed: 21775347
Oncologist. 2017 Sep;22(9):1049-1055
pubmed: 28778958
Gut. 2016 Apr;65(4):625-34
pubmed: 25654990
Atherosclerosis. 2005 Dec;183(2):308-15
pubmed: 16285994
Nat Rev Cancer. 2017 Apr;17(4):223-238
pubmed: 28233803
Nat Commun. 2018 Nov 29;9(1):5068
pubmed: 30498206
Ann N Y Acad Sci. 2000 Jun;908:244-54
pubmed: 10911963
Clin Epidemiol. 2016 Oct 25;8:465-468
pubmed: 27822086
Aging Cell. 2013 Jun;12(3):388-97
pubmed: 23438186
BMC Cancer. 2015 Oct 29;15:819
pubmed: 26514170
Clin Chem. 2015 Jan;61(1):112-23
pubmed: 25388429
Clin Chem. 2011 Apr;57(4):633-6
pubmed: 21296972